SAN DIEGO--(BUSINESS WIRE)--May 24, 2006--Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that a scientific presentation describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) was given at ATS 2006 -- San Diego, the annual International Conference of the American Thoracic Society.
